{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:15:25Z","timestamp":1753892125037,"version":"3.41.2"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,7,22]],"date-time":"2022-07-22T00:00:00Z","timestamp":1658448000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014717","name":"National Outstanding Youth Science Fund Project of National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82103902 81900526"],"award-info":[{"award-number":["82103902 81900526"]}],"id":[{"id":"10.13039\/100014717","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005198","name":"Chinese Foundation for Hepatitis Prevention and Control","doi-asserted-by":"publisher","award":["2021060"],"award-info":[{"award-number":["2021060"]}],"id":[{"id":"10.13039\/501100005198","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Aims:<\/jats:bold> To develop, optimize, and validate a novel model using alanine aminotransferase (ALT) and total bilirubin (TB) dynamic evolution patterns in predicting acute liver failure (ALF) in drug-induced liver injury (DILI) patients.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> The demographics, clinical data, liver biopsy, and outcomes of DILI patients were collected from two hospitals. According to the dynamic evolution of ALT and TB after DILI onset, the enrolled patients were divided into ALT-mono-peak, TB-mono-peak, double-overlap-peak, and double-separate-peak (DSP) patterns and compared. Logistic regression was used to develop this predictive model in both discovery and validation cohorts.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> The proportion of ALF was significantly higher in patients with the DSP pattern than in the ALT-mono-peak pattern and DOP pattern (10.0 vs. 0.0% vs. 1.8%,<jats:italic>p<\/jats:italic> &amp;lt; 0.05). The area under receiver operating characteristic curve (AUROC) of the DSP pattern model was 0.720 (95% CI: 0.682\u20130.756) in the discovery cohort and 0.828 (95% CI: 0.788\u20130.864) in the validation cohort in predicting ALF, being further improved by combining with international normalized ratio (INR) and alkaline phosphatase (ALP) (AUROC in the discovery cohort: 0.899; validation cohort: 0.958). Histopathologically, patients with the DSP pattern exhibited a predominantly cholestatic hepatitis pattern (75.0%, <jats:italic>p<\/jats:italic> &amp;lt; 0.05) with a higher degree of necrosis (29.2%, <jats:italic>p<\/jats:italic> = 0.084).<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> DILI patients with the DSP pattern are more likely to progress to ALF. The predictive potency of the model for ALF can be improved by incorporating INR and ALP. This novel model allows for better identification of high-risk DILI patients, enabling timely measures to be instituted for better outcome.<\/jats:p>","DOI":"10.3389\/fphar.2022.934467","type":"journal-article","created":{"date-parts":[[2022,7,23]],"date-time":"2022-07-23T02:38:05Z","timestamp":1658543885000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Alanine Aminotransferase and Bilirubin Dynamic Evolution Pattern as a Novel Model for the Prediction of Acute Liver Failure in Drug-Induced Liver Injury"],"prefix":"10.3389","volume":"13","author":[{"given":"Ruiyuan","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kexin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cailun","family":"Zou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aileen","family":"Wee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jimin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liwei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zikun","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingyi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Binxia","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingsheng","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jidong","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhengsheng","family":"Zou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,7,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/clpt.2011.58","article-title":"Case Definition and Phenotype Standardization in Drug-Induced Liver Injury","volume":"89","author":"Aithal","year":"2011","journal-title":"Clin. Pharmacol. Ther."},{"key":"B2","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.gastro.2005.05.006","article-title":"Drug-induced Liver Injury: an Analysis of 461 Incidences Submitted to the Spanish Registry over a 10-year Period","volume":"129","author":"Andrade","year":"2005","journal-title":"Gastroenterology"},{"key":"B3","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/liv.14271","article-title":"Diagnostic and Prognostic Assessment of Suspected Drug-Induced Liver Injury in Clinical Practice","volume":"40","author":"Andrade","year":"2020","journal-title":"Liver Int."},{"key":"B4","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1002\/hep.20800","article-title":"Outcome and Prognostic Markers in Severe Drug-Induced Liver Disease","volume":"42","author":"Bj\u00f6rnsson","year":"2005","journal-title":"Hepatology"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1053\/j.gastro.2008.09.011","article-title":"Causes, Clinical Features, and Outcomes from a Prospective Study of Drug-Induced Liver Injury in the United States","volume":"135","author":"Chalasani","year":"2008","journal-title":"Gastroenterology"},{"key":"B6","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3390\/ijms17010014","article-title":"RUCAM in Drug and Herb Induced Liver Injury: The Update","volume":"17","author":"Danan","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"B7","doi-asserted-by":"publisher","first-page":"4818","DOI":"10.3748\/wjg.v27.i29.4818","article-title":"New Hope for Hepatitis C Virus: Summary of Global Epidemiologic Changes and Novel Innovations over 20 Years","volume":"27","author":"Dennis","year":"2021","journal-title":"World J. Gastroenterol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the Management of Hepatitis B Virus Infection","volume":"67","year":"2017","journal-title":"J. Hepatol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1002\/hep.29283","article-title":"Death and Liver Transplantation within 2 Years of Onset of Drug-Induced Liver Injury","volume":"66","author":"Hayashi","year":"2017","journal-title":"Hepatology"},{"key":"B10","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1002\/hep.24060","article-title":"Unrecognized Acetaminophen Toxicity as a Cause of Indeterminate Acute Liver Failure","volume":"53","author":"Khandelwal","year":"2011","journal-title":"Hepatology"},{"key":"B11","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1002\/hep.26709","article-title":"Hepatic Histological Findings in Suspected Drug-Induced Liver Injury: Systematic Evaluation and Clinical Associations","volume":"59","author":"Kleiner","year":"2014","journal-title":"Hepatology"},{"key":"B12","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.gtc.2017.01.004","article-title":"Drug-induced Liver Injury: The Hepatic Pathologist's Approach","volume":"46","author":"Kleiner","year":"2017","journal-title":"Gastroenterol. Clin. North Am."},{"key":"B13","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1111\/liv.13584","article-title":"Histopathological Challenges in Suspected Drug-Induced Liver Injury","volume":"38","author":"Kleiner","year":"2018","journal-title":"Liver Int."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1002\/hep.510280533","article-title":"Early Hepatitis C Virus-RNA Responses Predict Interferon Treatment Outcomes in Chronic Hepatitis C","volume":"28","author":"Lee","year":"1998","journal-title":"Hepatology"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2360","DOI":"10.1016\/j.cgh.2015.06.020","article-title":"Risk of Acute Liver Failure in Patients with Drug-Induced Liver Injury: Evaluation of Hy's Law and a New Prognostic Model","volume":"13","author":"Lo Re","year":"2015","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/j.jhep.2016.05.003","article-title":"Definition and Risk Factors for Chronicity Following Acute Idiosyncratic Drug-Induced Liver Injury","volume":"65","author":"Medina-Caliz","year":"2016","journal-title":"J. Hepatol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1002\/hep.20703","article-title":"AASLD Position Paper: the Management of Acute Liver Failure","volume":"41","author":"Polson","year":"2005","journal-title":"Hepatology"},{"key":"B18","doi-asserted-by":"publisher","first-page":"F1000","DOI":"10.12688\/f1000research.20394.1","article-title":"Recent Advances in Alcoholic Hepatitis","volume":"9","author":"Rachakonda","year":"2020","journal-title":"F1000Res"},{"key":"B19","doi-asserted-by":"publisher","first-page":"100149","DOI":"10.1016\/j.jhepr.2020.100149","article-title":"Approach to the Patient with Acute Severe Autoimmune Hepatitis","volume":"2","author":"Rahim","year":"2020","journal-title":"JHEP Rep."},{"key":"B20","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1111\/apt.15153","article-title":"Consensus: Guidelines: Best Practices for Detection, Assessment and Management of Suspected Acute Drug-Induced Liver Injury during Clinical Trials in Patients with Nonalcoholic Steatohepatitis","volume":"49","author":"Regev","year":"2019","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B21","doi-asserted-by":"publisher","first-page":"724","DOI":"10.7326\/M15-2211","article-title":"Outcomes in Adults with Acute Liver Failure between 1998 and 2013: An Observational Cohort Study","volume":"164","author":"Reuben","year":"2016","journal-title":"Ann. Intern Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1053\/j.gastro.2014.03.050","article-title":"Use of Hy's Law and a New Composite Algorithm to Predict Acute Liver Failure in Patients with Drug-Induced Liver Injury","volume":"147","author":"Robles-Diaz","year":"2014","journal-title":"Gastroenterology"},{"key":"B23","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1053\/jhep.2002.34857","article-title":"Incidence of Drug-Induced Hepatic Injuries: a French Population-Based Study","volume":"36","author":"Sgro","year":"2002","journal-title":"Hepatology"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1053\/j.gastro.2019.02.002","article-title":"Incidence and Etiology of Drug-Induced Liver Injury in Mainland China","volume":"156","author":"Shen","year":"2019","journal-title":"Gastroenterology"},{"key":"B25","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/S0140-6736(19)31894-X","article-title":"Acute Liver Failure","volume":"394","author":"Stravitz","year":"2019","journal-title":"Lancet"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1038\/ajg.2012.138","article-title":"A Prospective Nationwide Study of Drug-Induced Liver Injury in Korea","volume":"107","author":"Suk","year":"2012","journal-title":"Am. J. Gastroenterol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1002\/pds.1211","article-title":"Hy's Law: Predicting Serious Hepatotoxicity","volume":"15","author":"Temple","year":"2006","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B28","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s40264-017-0547-9","article-title":"The Incidence of Drug- and Herbal and Dietary Supplement-Induced Liver Injury: Preliminary Findings from Gastroenterologist-Based Surveillance in the Population of the State of Delaware","volume":"40","author":"Vega","year":"2017","journal-title":"Drug Saf."},{"key":"B29","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s12072-019-09940-9","article-title":"A Proposed Pathologic Sub-classification of Drug-Induced Liver Injury","volume":"13","author":"Wang","year":"2019","journal-title":"Hepatol. Int."},{"key":"B30","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1007\/s12072-013-9424-5","article-title":"Changing Etiology of Liver Failure in 3,916 Patients from Northern China: a 10-year Survey","volume":"7","author":"You","year":"2013","journal-title":"Hepatol. Int."},{"key":"B31","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s12072-017-9793-2","article-title":"CSH Guidelines for the Diagnosis and Treatment of Drug-Induced Liver Injury","volume":"11","author":"Yu","year":"2017","journal-title":"Hepatol. Int."},{"key":"B32","doi-asserted-by":"publisher","first-page":"388","DOI":"10.21037\/hbsn-21-80","article-title":"Consensus Scoring Systems for Nonalcoholic Fatty Liver Disease: an Unmet Clinical Need","volume":"10","author":"Zhou","year":"2021","journal-title":"Hepatobiliary Surg. Nutr."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.934467\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,23]],"date-time":"2022-07-23T02:38:09Z","timestamp":1658543889000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.934467\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,22]]},"references-count":32,"alternative-id":["10.3389\/fphar.2022.934467"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.934467","relation":{},"ISSN":["1663-9812"],"issn-type":[{"type":"electronic","value":"1663-9812"}],"subject":[],"published":{"date-parts":[[2022,7,22]]},"article-number":"934467"}}